Barriers to Chimeric Antigen Receptor T-Cell Therapy.
作者信息
Valtis Yannis K, Chin Kuo-Kai, Nemirovsky David, Devlin Sean M, Yisraeli Salman Meira, Boussi Leora, Cadzin Briana, McLoughlin Carina, Cathcart Elizabeth, Davis Paul, Brooklyn Chelsea, Goldstein Todd, Famulare Chris, Shah Gunjan L, Walji Moneeza, Scordo Michael, Boardman Alexander P, Shouval Roni, Stein Eytan M, Geyer Mark B, Mailankody Sham, Palomba M Lia, Usmani Saad Z, Salles Gilles, Giralt Sergio A, Perales Miguel-Angel, Park Jae H
机构信息
Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
出版信息
JAMA Oncol. 2025 May 15. doi: 10.1001/jamaoncol.2025.1127.
Abstract
摘要
相似文献
1
Barriers to Chimeric Antigen Receptor T-Cell Therapy.
JAMA Oncol. 2025 May 15. doi: 10.1001/jamaoncol.2025.1127.
2
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2.
3
Revaccination following CAR-T therapy: a needs assessment.
Hematology. 2025 Dec;30(1):2519865. doi: 10.1080/16078454.2025.2519865. Epub 2025 Jun 23.
4
Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
Transplant Cell Ther. 2022 Jun;28(6):294-302. doi: 10.1016/j.jtct.2022.03.006. Epub 2022 Mar 11.
5
Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell Therapy.
Transplant Cell Ther. 2022 Jun;28(6):305.e1-305.e9. doi: 10.1016/j.jtct.2022.03.023. Epub 2022 Apr 1.
6
Neuropsychiatric manifestations following chimeric antigen receptor T cell therapy for cancer: a systematic review of clinical outcomes and management strategies.
J Immunother Cancer. 2024 Dec 22;12(12):e009174. doi: 10.1136/jitc-2024-009174.
7
Cancer-related cognitive impairment in patients with hematologic malignancies after CAR T cell therapy: a systematic review and meta-analysis of prevalence.
Support Care Cancer. 2025 Mar 22;33(4):312. doi: 10.1007/s00520-025-09356-2.
8
5-5-5 ABRT (Dose of 5 Gy per Fraction for up to 5 Fractions Over 5 Weeks Adaptive Bridging Radiation Therapy)-Artificial Intelligence Enters the CAR (-T) (Chimeric Antigen Receptor-T) in Relapsed/Refractory Large B Cell Lymphoma.
Int J Radiat Oncol Biol Phys. 2025 Jul 15;122(4):936-948. doi: 10.1016/j.ijrobp.2025.03.023. Epub 2025 Apr 3.
9
A new sort of cells for chimeric antigen receptor T-cell therapies-isolating CD14CD127 T cells for chimeric antigen receptor T-cell manufacture.
Cytotherapy. 2025 Apr 18. doi: 10.1016/j.jcyt.2025.04.068.
10
A meta-analysis to assess the risk of bleeding and thrombosis following chimeric antigen receptor T-cell therapy: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy.
J Thromb Haemost. 2024 Jul;22(7):2071-2080. doi: 10.1016/j.jtha.2024.03.021. Epub 2024 Apr 2.
本文引用的文献
1
Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network.
Blood Adv. 2025 Jan 28;9(2):429-435. doi: 10.1182/bloodadvances.2024014171.
2
Real-World Analysis of Barriers to Timely Administration of Chimeric Antigen Receptor T Cell (CAR T) Therapy in Diffuse Large B-cell Lymphoma.
Transplant Cell Ther. 2024 Nov;30(11):1082.e1-1082.e10. doi: 10.1016/j.jtct.2024.09.007. Epub 2024 Sep 11.
3
Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel.
Blood Adv. 2024 Oct 22;8(20):5346-5354. doi: 10.1182/bloodadvances.2023012549.
4
CAR T-Cell Immunotherapy in Minority Patients with Lymphoma.
NEJM Evid. 2024 Apr;3(4):EVIDoa2300213. doi: 10.1056/EVIDoa2300213. Epub 2024 Mar 26.
5
Long-term outcomes following CAR T cell therapy: what we know so far.
Nat Rev Clin Oncol. 2023 Jun;20(6):359-371. doi: 10.1038/s41571-023-00754-1. Epub 2023 Apr 13.
6
Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Transplant Cell Ther. 2023 Jul;29(7):440-448. doi: 10.1016/j.jtct.2023.04.003. Epub 2023 Apr 7.
Zotero 插件